Kashyap Patel, MD: Biosimilars and Cost in Part B

Kashyap Patel, MD, discusses how biosimilars impact cost in the Medicare Part B context.
August 14, 2019



Transcript

Biosimilars are really a very good solution to the ever-rising Part B drug price, and they have directed the reference biologic manufacturers to come and become competitive. That’s how we’re seeing the subcutaneous molecule for rituximab, which actually is going to be standing up firm against the biosimilar in the market.

Any competition in the market helps improve the cost, helps improve the patient’s convenience, and helps the physicians as well. So at the end of the day, it’s all about treating patients right, saving dollar volume for the Part B drug space, and doing good for all.  
 

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.